Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Acta Psychologica
|
March 1, 1980
Slow brain potentials in the CNV-paradigm
A W Gaillard, J Perdok
Biological Psychology
|
May 1, 1979
The terminal CNV and stimulus discriminability in motor and sensory tasks
J Perdok, A W Gaillard
Acta Psychologica
|
May 1, 1979
Slow cortical and heart rate correlates of discrimination performance
A W Gaillard, J Perdok
Progress in Brain Research
|
January 1, 1980
Motor preparation at a cortical and at a peripheral level
A W Gaillard, J Perdok, C A Varey
International Archives of Allergy and Immunology
|
May 1, 1997
Mouse/human chimeric antibodies directed to two nonoverlapping epitopes of the house dust mite allergen, Der p 2
J Schuurman, G J Perdok, R C Aalberse
Molecular Immunology
|
August 3, 2001
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds
J Schuurman, G J Perdok, A D Gorter, et al.
The Journal of Allergy and Clinical Immunology
|
April 3, 1998
Complementation of Der P 2-induced histamine release from human basophils sensitized with monoclonal IgE: not only by IgE, but also by IgG antibodies directed to a nonoverlapping epitope of Der p 2
J Schuurman, G J Perdok, G A Mueller, et al.
International Archives of Allergy and Immunology
|
May 1, 1995
Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2
J Schuurman, T E Lourens, G J Perdok, et al.
Annals of the Rheumatic Diseases
|
October 19, 2006
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
D D Gladman, P J Mease, M A Cifaldi, et al.
Journal of the American Academy of Dermatology
|
December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial
Alexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Acta Psychologica
|
March 1, 1980
Slow brain potentials in the CNV-paradigm
A W Gaillard, J Perdok
Biological Psychology
|
May 1, 1979
The terminal CNV and stimulus discriminability in motor and sensory tasks
J Perdok, A W Gaillard
Acta Psychologica
|
May 1, 1979
Slow cortical and heart rate correlates of discrimination performance
A W Gaillard, J Perdok
Progress in Brain Research
|
January 1, 1980
Motor preparation at a cortical and at a peripheral level
A W Gaillard, J Perdok, C A Varey
International Archives of Allergy and Immunology
|
May 1, 1997
Mouse/human chimeric antibodies directed to two nonoverlapping epitopes of the house dust mite allergen, Der p 2
J Schuurman, G J Perdok, R C Aalberse
Molecular Immunology
|
August 3, 2001
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds
J Schuurman, G J Perdok, A D Gorter, et al.
The Journal of Allergy and Clinical Immunology
|
April 3, 1998
Complementation of Der P 2-induced histamine release from human basophils sensitized with monoclonal IgE: not only by IgE, but also by IgG antibodies directed to a nonoverlapping epitope of Der p 2
J Schuurman, G J Perdok, G A Mueller, et al.
International Archives of Allergy and Immunology
|
May 1, 1995
Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2
J Schuurman, T E Lourens, G J Perdok, et al.
Annals of the Rheumatic Diseases
|
October 19, 2006
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
D D Gladman, P J Mease, M A Cifaldi, et al.
Journal of the American Academy of Dermatology
|
December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial
Alexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Page
of 3